Framingham Study Offers Mixed Message on Galectin-3 as Heart Failure Risk Marker | GenomeWeb

This story has been updated to correct a quote citing a BG official saying BNP is a marker of inflammation. In fact, he said that it was a marker of "loading and stretch."

Researchers from the National Heart, Lung and Blood Institute's Framingham Heart Study have published data suggesting the protein galectin-3 could serve as a prognostic biomarker for heart failure, but the clinical utility of the marker is still uncertain.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.